272 results about "A baumannii" patented technology

The invention relates to the technical field of antibacterial peptide application, in particular to an antibacterial peptide for inhibiting drug-resistant acinetobacter baumannii as well as a preparation method and application of the antibacterial peptide. The antibacterial peptide is cd77AHP-2, and the amino acid sequence of the antibacterial peptide is shown as SEQ ID NO.1. The antibacterial peptide cd77 obtained through artificial chemical synthesis is modified, distribution of cationic amino acid is optimized, and the antibacterial activity of the antibacterial peptide is remarkably improved. The antibacterial peptide cd77AHP-2 has a remarkable antibacterial effect on acinetobacter baumannii which are gram-negative bacteria and multi-drug resistant acinetobacter baumannii, and the antibacterial peptide cd77AHP-2 has a remarkable antibacterial effect on the acinetobacter baumannii which are gram-negative bacteria. The antibacterial peptide cd77AHP-2 provided by the invention has relatively low cytotoxicity to human bronchial epithelial cells, and has the potential of preparing a drug for resisting drug-resistant acinetobacter baumannii. The invention provides a novel functional polypeptide for the field of antibacterial peptides, and the novel functional polypeptide has important practical application value.

The invention belongs to the field of antibacterial peptides, and particularly relates to an antibacterial peptide with a broad-spectrum antibacterial effect, an antibacterial product and application. The antibacterial peptide is named as CAMP1111NC, and is obtained by performing N-terminal acetyl end capping and C-terminal amino end capping on polypeptide shown in SEQ ID NO: 1. The antibacterial peptide has remarkable antibacterial activity on a staphylococcus aureus standard strain ATCC12600, pseudomonas aeruginosa PAO1, klebsiella pneumoniae, an acinetobacter baumannii standard strain ATCC19606, methicillin-resistant staphylococcus aureus ATCC33591, methicillin-resistant and gentamicin-resistant staphylococcus aureus ATCC33592 and acinetobacter baumannii bio-53272 resistant to various antibiotics, and the antibacterial peptide can be used for preparing the antibacterial peptide. The limitation of the traditional antibacterial peptide is effectively overcome.

The invention provides an aerobic denitrifying bacterium with zoogloea character and application thereof, and belongs to the technical field of wastewater treatment, the aerobic denitrifying bacterium is specifically acinetobacter baumannii N-1 (Acinetobacter sp.N-1), the acinetobacter baumannii is preserved in the China Center for Type Culture Collection, and the preservation number is CCTCC NO: M 20242568. The acinetobacter baumannii N-1 provided by the invention not only can perform wastewater denitrification through aerobic denitrification and has efficient denitrification capacity, but also can realize separation of sludge and purified water by forming zoogloea, so that the acinetobacter baumannii N-1 has good application potential in wastewater treatment by utilizing an activated sludge process.

The invention belongs to the technical field of antibacterial peptides, and particularly relates to an antibacterial peptide and application thereof. The amino acid sequence of the antibacterial peptide is shown as SEQ ID NO: 1, the number of amino acids is small, the synthesis cost is low, the antibacterial peptide has high antibacterial activity on gram-negative bacteria and gram-positive bacteria, the minimum inhibitory concentration of the antibacterial peptide on acinetobacter baumannii, escherichia coli, pseudomonas aeruginosa and staphylococcus aureus is 4.68-37.5 mu g / mL, and the antibacterial peptide has the advantages of broad-spectrum antibacterial property, good stability and good application prospect. No obvious cytotoxicity and hemolysis effect exist; moreover, end-to-end amido bond cyclization is carried out, so that the antibacterial activity is further enhanced, the antibacterial effect on acinetobacter baumannii, escherichia coli, pseudomonas aeruginosa and staphylococcus aureus is enhanced by 2-4 times, and the minimum inhibitory concentration is reduced to 2.34-9.38 mu g / mL; after the end-to-end amido bonds are cyclized, the plasma stability and safety of the antibacterial peptide are further improved, and the cytotoxicity and hemolysis are reduced.

The invention relates to the technical field of high-throughput targeted sequencing, in particular to a primer group for detecting important drug-resistant genes and virulence genes of multi-drug-resistant pathogenic bacteria and application of the primer group. Specifically, the kit comprises detection primers for multiple drug-resistant bacteria such as third-generation cephalosporin drug-resistant enterobacteriaceae bacteria, carbapenem drug-resistant enterobacteriaceae bacteria, carbapenem drug-resistant acinetobacter baumannii, rifampicin drug-resistant mycobacterium tuberculosis and the like. The method has the technical advantages of rapidness, high efficiency, strong targeting property, strong specificity and the like, is suitable for epidemic and difference analysis of various important drug-resistant genes and virulence genes carried by metagenome samples of various environments or disease materials and the like, evaluates the risk of related environments on the basis, and can further guide prevention and clinical treatment medication.

The present invention provides an ATP phosphoribosyltransferase mutant and its application in histidine production. The mutant is obtained by performing point mutations at positions 84 and / or 205 on the amino acid sequence of the wild-type ATP phosphoribosyltransferase derived from Acinetobacter baumannii. The mutant, the nucleic acid molecule encoding the mutant, the expression cassette containing the nucleic acid molecule, the recombinant vector or the recombinant microorganism are used for the production of L-histidine, and the yield of L-histidine is significantly increased, laying a good foundation for the large-scale industrial production of L-histidine.

The invention belongs to the technical field of medicines, and discloses a near-infrared cyanine probe for detecting penicillin G acylase as well as a preparation method and application of the near-infrared cyanine probe. According to the research, a near-infrared fluorescent probe Cy-NEO-PA responding to penicillin G acylase (PGA) is developed, so that the influence of environmental factors on the formation of an acinetobacter baumannii biological membrane is observed. Research results show that glucose inhibits the generation of PGA to enhance the formation of a biological membrane, while phenylacetic acid (PAA) stimulates the generation of PGA and inhibits the formation of the biological membrane. The observation results highlight the excellent capability of Cy-NEO-PA in accurately measuring PGA kinetics, and reveal the key effect of PGA in biological membrane development. In addition, the Cy-NEO-PA has good biocompatibility, strong active oxygen generation, efficient photo-thermal conversion and bacterial targeting ability, so that the Cy-NEO-PA becomes a promising drug for resisting bacterial infection and promoting wound healing through photo-thermal / photodynamic therapy.

The invention discloses a bacillus strain H7 and an application thereof. The invention provides bacillus velezensis H7 or a progeny of the bacillus velezensis H7, and the preservation number of the bacillus velezensis H7 in the China Center for Type Culture Collection (CCTCC) is CCTCC NO: M 2025630. The bacillus velezensis H7 disclosed by the invention has a very good antibacterial effect on various common clinical pathogenic bacteria (including klebsiella pneumoniae, escherichia coli, candida albicans, enterobacter cloacae complex, acinetobacter baumannii and the like), and particularly shows a very high inhibition rate on some drug-resistant clinical pathogenic bacteria; therefore, the compound has important application value in development of drug and non-drug antibacterial products (such as medical antibacterial materials and the like), a new choice can be provided for drug and non-drug prevention and control of clinical pathogenic bacterium infection, and particularly, the compound has a supplementary effect in the aspects of reducing drug-resistant bacterium propagation risk and reducing drug dependence.

The invention discloses application of acinetobacter baumannii bacteriophage depolymerases in preparation of bacteriostatic agents, and relates to the technical field of biology. The depolymerases disclosed by the invention can inhibit the growth of a plurality of acinetobacter baumannii, have a bacteriostatic effect on the acinetobacter baumannii, and lay a foundation for developing effective infection control strategies and treatment methods to resist infection of the multi-drug-resistant acinetobacter baumannii.

The invention relates to an acinetobacter baumannii resistant cyclic peptide and application thereof, in particular to a compound shown in a formula (I), a tautomer, a stereoisomer, a hydrate, a solvate, pharmaceutically acceptable salt or prodrug of the compound and a preparation method of the tautomer, the stereoisomer, the hydrate, the solvate and the pharmaceutically acceptable salt or prodrug of the compound. The invention further discloses application of the acinetobacter baumannii in preparation of drugs for treating or preventing infection and diseases caused by the acinetobacter baumannii. # imgabs0 #

The invention relates to a broad-spectrum antibacterial peptide 910302 and application thereof, and relates to the technical field of biology. The antibacterial peptide has broad-spectrum antibacterial activity, can inhibit gram-positive bacteria such as staphylococcus aureus, gram-negative bacteria such as escherichia coli, klebsiella pneumoniae, acinetobacter baumannii and pseudomonas aeruginosa, and fungi such as candida auriculata and candida albicans, and has high antibacterial activity. The compound has a relatively strong inhibition effect on clinically separated drug-resistant strains with multiple drug resistance. In addition, the antibacterial peptide is low in hemolytic activity, small in toxicity, short in synthetic sequence, small in molecular weight and easy to chemically synthesize. And the in-vivo safety is ensured while efficient sterilization is realized.

The invention belongs to the technical field of antibacterial peptides, and particularly relates to an antibacterial peptide Mh-GC21 as well as a precursor and application thereof. The amino acid sequence of the antibacterial peptide Mh-GC21 provided by the invention is as shown in SEQ ID NO.1, and two cysteines are oxidized to form a pair of intermolecular disulfide bonds; the C tail end of the antibacterial peptide Mh-GC21 is subjected to amidation modification. The antibacterial peptide Mh-GC21 provided by the invention is from microhyla microcarpa, has broad-spectrum antibacterial activity, has relatively good antibacterial and bactericidal effects on standard strains of acinetobacter baumannii, escherichia coli and staphylococcus aureus and clinically sourced drug-resistant strains, and can be used for targeted destruction of cell membranes of bacteria, removal of biological membranes and inhibition of formation of the biological membranes. Moreover, the antibacterial peptide Mh-GC21 has the advantages of good stability, no hemolytic activity and cytotoxicity, and difficulty in inducing strains to generate drug resistance.

The invention discloses an acinetobacter baumannii outer membrane protein liposome vaccine as well as a preparation method and application thereof, and relates to the field of biological medicines. The acinetobacter baumannii outer membrane protein liposome vaccine is obtained by efficiently expressing the acinetobacter baumannii outer membrane protein through a genetic engineering means and combining the obtained multiple outer membrane proteins as antigens with a lipid mixture and an adjuvant, and the acinetobacter baumannii outer membrane protein liposome vaccine is proved to be capable of providing complete protection for mice challenged by lethal dose acinetobacter baumannii. Wherein the outer membrane protein loaded by the lipidosome realizes structural refolding, the protein immunogenicity is enhanced, and the lipidosome can reduce the toxicity of the outer membrane protein; omp38 + BauA + FimA may be an effective antigen combination for preventing acinetobacter baumannii infection; as a TLR2 agonist, Pam2CSK4 has a strong auxiliary effect on an acinetobacter baumannii liposome vaccine, can induce innate immune response activation, and provides a more comprehensive protection effect on a host.

The invention discloses acinetobacter baumannii and application of the acinetobacter baumannii in construction of a mastitis animal model. The acinetobacter baumannii strain is acinetobacter baumannii AbST3475NMG202308, and the preservation number of the acinetobacter baumannii strain is CGMCC (China General Microbiological Culture Collection Center) No.34450 in the General Microbiological Culture Collection Center of the China Committee for Culture Collection of Microorganisms). Experiments prove that the acinetobacter baumannii has high pathogenicity and can be used for establishing a typical animal model caused by acinetobacter baumannii infection, the animal model can be specifically a mastitis animal model, and a certain technical support is provided for subsequent research and development of drugs or vaccines; the acinetobacter baumannii can also be used for screening antibacterial drugs and developing diagnostic reagents and vaccines. The method has an important application value.

The invention discloses an application of NSC348884 in preparation of an antibacterial drug, the bacteria of the NSC348884 are gram-negative bacteria or drug-resistant gram-negative bacteria, and the gram-negative bacteria are acinetobacter baumannii, escherichia coli, pseudomonas aeruginosa or klebsiella pneumoniae; based on an antibacterial drug high-throughput screening technology, it is found from 1280 small molecule compounds that the benzimidazole compound NSC348884 has direct bacteriostasis and sterilization effects on gram-negative bacteria and drug-resistant gram-negative bacteria, and no drug resistance is generated after the benzimidazole compound NSC348884 is continuously applied for 14 days. Further research shows that NSC348884 can interfere with lipid synthesis of gram-negative bacterium cell membranes, inhibit formation of biological membranes and induce lipid metabolism disorder, so that bacteriostatic and bactericidal effects are achieved. In addition, the NSC348884 can also enhance the sensitivity of the drug-resistant bacteria to the imipenem and the polymyxin B.

The invention relates to the technical field of antibacterial peptide application, in particular to an antibacterial peptide cAMP-1116nc with a broad-spectrum antibacterial effect and application of the antibacterial peptide cAMP-1116nc. The antibacterial peptide cAMP-1116nc is obtained by carrying out N-terminal acetylation modification and C-terminal amidation modification on a polypeptide as shown in SEQ ID NO. 1. The antibacterial peptide cAMP-1116nc is an antibacterial peptide cAMP-1116nc. The antibacterial peptide cAMP-1116nc disclosed by the invention shows remarkable antibacterial activity in a plurality of gram-positive bacteria and gram-negative bacteria. The antibacterial peptide cAMP-1116nc can efficiently kill clinically common gram-negative pathogenic bacteria acinetobacter baumannii under the conditions that the pH is equal to 2, the pH is equal to 7.4 and the pH is equal to 8.4, has relatively low cytotoxicity, has the potential of preparing antibacterial drugs, and is suitable for developing antibacterial products with multiple purposes, including the antibacterial drugs, disinfectants and biological preservatives. The invention provides a novel functional polypeptide for the field of antibacterial peptides, and the novel functional polypeptide has important practical application value.

The invention discloses a preparation process of acinetobacter baumannii extracellular protein OmpA, which comprises the following steps: (1) seeds are inoculated into a seed culture medium for primary culture, then secondary culture is carried out, IPTG (isopropyl-beta-d-thiogalactoside) is added, induction is carried out for 3-5 hours, and the culture medium comprises yeast powder, a nitrogen source and salt; (2) centrifuging, collecting thalli, and crushing the thalli; (3) dissolving and solubilizing the inclusion body, namely dissolving 1.0 g of precipitate in 10mL of solution, centrifuging, and collecting supernate; (4) anion amp; carrying out cation chromatography; (5) dilution and renaturation: diluting with a renaturation solution with the pH value of 7.5 by using 20mM PB, renaturating overnight, centrifuging, and waiting for column loading; (6) cation chromatography; and (7) dialyzing and changing the solution. The protein purity (SDS-PAGE) of the acinetobacter baumannii extracellular protein OmpA prepared by the method disclosed by the invention is more than 99%, and the protein yield is 15.4 mg / g inclusion body.

The invention provides a fluorenyl alcohol derivative which can be used as an antibiotic adjuvant with a broad-spectrum synergistic effect. According to the compound, bacteria outer membrane asymmetric protein MlaC and phospholipase A1 PldA are taken as targets, and a series of fluorenyl alcohol derivatives targeting the bacteria outer membrane asymmetric protein MlaC and phospholipase A1 PldA are obtained through screening. The preferable compound WTU-15 can improve the antibacterial activity of antibiotics such as polymyxin, cefepime, tetracycline and the like on negative bacteria such as sensitive and drug-resistant escherichia coli, salmonella, klebsiella pneumoniae, acinetobacter baumannii and the like, and can also improve the in-vivo treatment effect of cefepime on mice infected by the drug-resistant acinetobacter baumannii. And the visceral organs of the mice survived after administration have fewer bacteria, and the mice are better after being healed. Normal physiological and visceral organ functions of the mouse are not affected by single and continuous administration of the WTU-15.

The present invention relates to the technical field of phages. Provided are a KL2-type Acinetobacter baumannii phage and a screening method therefor, a phage composition and the use, and a drug. The KL2-type Acinetobacter baumannii phage is named AB_SZL2, and is deposited in the China Center for Type Culture Collection with the deposit number CCTCC NO: M20241522; or the KL2-type Acinetobacter baumannii phage is named AB_SZL3, and is deposited in the China Center for Type Culture Collection with the deposit number CCTCC NO: M20241523. The KL2-type Acinetobacter baumannii phage can accurately target KL2-type Acinetobacter baumannii, and has an efficient bactericidal effect, thereby reducing the harm of KL2-type Acinetobacter baumannii and effectively addressing the problem of the antibiotic resistance of KL2-type Acinetobacter baumannii.

The invention belongs to the field of antibacterial peptides, and particularly relates to an antibacterial peptide with a broad-spectrum antibacterial effect, an antibacterial product and application. The antibacterial peptide is named as CAMP502NC, and is obtained through N-terminal acetyl end capping and C-terminal amino end capping of polypeptide shown in SEQ ID NO: 1. The antibacterial peptide has remarkable antibacterial activity on a staphylococcus aureus standard strain ATCC12600, pseudomonas aeruginosa PAO1, klebsiella pneumoniae, an acinetobacter baumannii standard strain ATCC19606, methicillin-resistant staphylococcus aureus ATCC33591, methicillin-resistant and gentamicin-resistant staphylococcus aureus ATCC33592 and acinetobacter baumannii bio-53272 resistant to various antibiotics, and the antibacterial peptide can be used for preparing the antibacterial peptide. The limitation of the traditional antibacterial peptide is effectively overcome.

The invention belongs to the field of chemical synthesis, and particularly relates to four acinetobacter baumannii cell wall oligosaccharide fragments as well as a synthesis method and application thereof. Four acinetobacter baumannii core oligosaccharide fragments are synthesized by adopting a divergent synthesis strategy, compounds 1-3 take orthogonally protected alpha-(2-> 5)-Kdo-Kdo disaccharide as key precursors, protecting groups at different sites are selectively removed, glycosyl is introduced through a stereoselective glycosylation reaction, and thus a target molecular skeleton is constructed. The method disclosed by the invention and the four finally prepared acinetobacter baumannii core oligosaccharide fragments have huge industrial application potential.

The invention discloses an Acinetobacter baumannii H5 strain and application thereof, the Acinetobacter baumannii H5 strain is preserved in the Guangdong Microbial Culture Collection Center on September 29, 2024, and the preservation number is GDMCC (China General Microbiological Culture Collection Center) NO: 65133; and the strain has a good degradation effect on polyethylene glycol terephthalate plastics. As the spodoptera frugiperda is a recently occurring major invading pest, domestic and overseas scholars are very limited in research on intestinal microorganisms of the spodoptera frugiperda, no related report about that intestinal strains of the spodoptera frugiperda can effectively degrade polyethylene glycol terephthalate exists at present, and the research on the degradation mechanism of the spodoptera frugiperda is also relatively lacked. The Acinetobacter baumannii H5 can enrich a plastic degradation microorganism germplasm resource library, provides the most basic resource for the technical breakthrough of polyethylene glycol terephthalate biodegradation, and also can optimize the ecological environment protection.

The invention belongs to the technical field of biology, and particularly relates to a primer probe composition and a kit for detecting lower respiratory tract infection pathogens. The primer probe composition is used for detecting mycobacterium tuberculosis, mycobacterium avium, mycobacterium abscessus, mycobacterium kansasii, pseudomonas aeruginosa, klebsiella pneumoniae, acinetobacter baumannii and haemophilus influenzae, and the primer probe composition is used for detecting mycobacterium tuberculosis, mycobacterium avium, mycobacterium abscessus, mycobacterium kansasii, pseudomonas aeruginosa, klebsiella pneumoniae, acinetobacter baumannii and haemophilus influenzae. The composition is one or more of a composition for detecting staphylococcus aureus, a composition for detecting streptococcus pneumoniae, a composition for detecting escherichia coli, a composition for detecting moraxella catarrhalis, a composition for detecting serratia marcescens, a composition for detecting mycoplasma pneumoniae, a composition for detecting candida albicans or a composition for detecting adenovirus; the RAA-RDB technology has the core advantages of rapidness, high sensitivity, low cost and easy operation, and is especially suitable for multiple pathogen screening and basic medical application.

The invention relates to the technical field of application of antibacterial peptides, in particular to a broad-spectrum bacterial-source antibacterial peptide cAMP-919nc and application of the broad-spectrum bacterial-source antibacterial peptide cAMP-919nc. The antibacterial peptide cAMP-919nc is obtained by carrying out N-terminal acetylation modification and C-terminal amidation modification on a polypeptide as shown in SEQ ID NO.1. The invention further discloses a preparation method of the antibacterial peptide cAMP-919nc. The antibacterial peptide shows an excellent antibacterial effect in various bacteria, and particularly, the minimum inhibitory concentration of the antibacterial peptide to staphylococcus aureus is as low as 4 mu g / mL. Under different pH conditions, the antibacterial peptide also shows remarkable bactericidal activity on gram-negative pathogenic bacteria acinetobacter baumannii. In addition, the peptide has extremely low cytotoxicity and shows good safety. The invention provides the antibacterial peptide with excellent performance, and the antibacterial peptide has wide application potential and can be used for developing various antibacterial products such as antibacterial drugs, disinfectants and biological preservatives. The invention opens up a new direction for the research and application of the antibacterial peptide, and has important scientific and practical values.

The invention provides a primer probe combination and a kit for detecting acinetobacter baumannii, stenotrophomonas maltophilia and burkholderia cepacia, and relates to the technical field of biology. The primer probe combination provided by the invention comprises a primer and a probe for detecting the acinetobacter baumannii, the stenotrophomonas maltophilia and the burkholderia cepacia, and can be used for accurately and quickly identifying the acinetobacter baumannii, the stenotrophomonas maltophilia and the burkholderia cepacia in a reaction system at the same time; and the kit has good specificity and sensitivity (the lowest detection limit on acinetobacter baumannii, stenotrophomonas maltophilia and burkholderia cepacia is 50 CFU / mL).

The invention relates to an antibacterial peptide and application thereof. The amino acid sequence of the antibacterial peptide is as shown in SEQ ID No. 1. The antibacterial peptide has excellent broad-spectrum antibacterial activity, for example, the antibacterial peptide has antibacterial activity on bacteria of the genus Staphylococcus (Staphylococcus), the genus Acinetobacter (Acinetobacter) and the genus Bacillus (Bacillus). Under the background that the global bacterial drug resistance problem is increasingly severe and traditional antibiotics gradually lose efficacy on multi-drug-resistant bacteria, a new treatment means is provided for treating bacteria such as methicillin-resistant staphylococcus aureus, carbapenem-resistant acinetobacter baumannii and bacillus subtilis which bring huge threats to public health. And a new possibility is provided for solving the problem that no medicine can be used clinically.

The invention discloses acinetobacter baumannii and application thereof.The acinetobacter baumannii is preserved in Guangdong Microbial Culture Collection Center on August 16, 2024, the preservation number is GDMCC No: 65015, the acinetobacter baumannii has a good denitrification effect, and the degradation rate of ammonia nitrogen reaches 94.93%; the degradation rate on nitrate reaches 99.53%; and the degradation rate of nitrite reaches 96.94%. The immobilized microbial agent is further prepared from the bacillus subtilis and pseudomonas aeruginosa with vibrio parahaemolyticus resistance, and the immobilized microbial agent has good effects in the aspects of denitrification and vibrio parahaemolyticus resistance, especially shows better denitrification effect and antibacterial effect in actual culture application, and has good application prospects.

The invention belongs to the technical field of bacterium detection, and discloses a multiple PCR primer for simultaneously detecting eight respiratory tract pathogenic bacteria and application thereof. On the basis of a Luminex liquid phase chip technology, specific primers are designed aiming at eight common respiratory tract infection pathogenic bacteria including pseudomonas aeruginosa, staphylococcus aureus, streptococcus pneumoniae, klebsiella pneumoniae, acinetobacter baumannii, stenotrophomonas maltophilia, haemophilus influenzae and escherichia coli; the multiple PCR primers which are high in amplification efficiency, good in specificity and suitable for simultaneously detecting the eight respiratory tract pathogenic bacteria are screened out, the multiple PCR system and microsphere hybridization conditions are continuously optimized, the multiple PCR method for the eight respiratory tract pathogenic bacteria is successfully constructed by applying the Luminex xTAG technology, and the multiple PCR method can be applied to rapid detection of multiple pathogenic microorganisms.

The invention discloses application of a cyclic peptide compound BIM 23042 or a preparation thereof in preparation of medicines for treating bacterial infectious diseases, and belongs to the technical field of medicines. The invention discloses a cyclic peptide compound BIM 23042 as an antibiotic synergist for the first time, and the cyclic peptide compound BIM 23042 is used for treating bacterial infectious diseases. According to the application disclosed by the invention, the cyclopeptide compound BIM 23042 and polymyxin are combined for use, so that the growth of gram-negative bacteria can be effectively and synergistically inhibited. The combined medication scheme shows a remarkable advantage in coping with acinetobacter baumannii. The cyclic peptide compound BIM 23042 disclosed by the invention has an anti-infection capability, and the anti-infection capability is specifically shown as reducing the inflammatory response of macrophage RAW 264.7 induced by LPS (Lipopolysaccharide) and also reducing the apoptosis of the macrophage RAW 264.7 caused by the LPS. The invention provides a new perspective for developing a novel drug-resistant gram-negative bacterium prevention and control strategy, and also provides a new treatment scheme for coping with bacterial infection.

The invention belongs to the technical field of strain identification and drug sensitivity detection, and discloses a strain identification and drug sensitivity detection kit and a preparation method and application thereof, the kit comprises a drug sensitivity disc, a pre-enrichment chromogenic culture medium, a chromogenic culture medium, sterile water and a diluent; the drug sensitive disc body comprises an enterobacteriaceae area, an enterococcus area, a staphylococcus area, a pseudomonas aeruginosa area and an acinetobacter baumannii area; the enterobacteriaceae area is provided with enterobacteriaceae identification culture medium micropores and drug micropores, the enterococcus area is provided with enterococcus identification culture medium micropores and drug micropores, the staphylococcus area is provided with staphylococcus identification culture medium micropores and drug micropores, and the pseudomonas aeruginosa area is provided with pseudomonas aeruginosa identification culture medium micropores and drug micropores. An acinetobacter baumannii identification culture medium micropore and a medicine micropore are matched in the acinetobacter baumannii area; the problems that an existing drug sensitivity test mode is complex in operation, high in cost and low in accuracy of identification and detection results are solved.